Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria
about
HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneityMicrofluidic platform combining droplets and magnetic tweezers: application to HER2 expression in cancer diagnosis.Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guidelineCentral pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study.A nomogram to predict the probability of axillary lymph node metastasis in female patients with breast cancer in China: A nationwide, multicenter, 10-year epidemiological study.In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patientsRecommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases.Preoperative serum HER2 extracellular domain levels in primary invasive breast cancerAn integrated model of the transcriptome of HER2-positive breast cancer.Optimal systemic therapy for early breast cancer in women: a clinical practice guidelineIn the era of genomics, should tumor size be reconsidered as a criterion for neoadjuvant chemotherapy?EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trialCytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant basal-HER2 subtype of breast cancer.The Globalization of Cooperative Groups.Adjuvant treatment of HER2-positive breast cancer: winning efforts continue to improve HER2-positive patient outcome long-term.How relevant is hormone receptor status in the context of outcome to HER2-positive breast cancer?PIK3CA(H1047R)- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling.HER-2 gene amplification in human breast cancer without concurrent HER-2 over-expression.Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding.Current Challenges for HER2 Testing in Diagnostic Pathology: State of the Art and Controversial Issues.The classification of invasive carcinoma of the breast.HER2 assessment by silver in situ hybridization: where are we now?HER2 testing and its predictive utility in anti-HER2 breast cancer therapy.Breast carcinomas with low amplified/equivocal HER2 by Ish: potential supporting role of multiplex ligation-dependent probe amplification.Nuclear receptors in cancer - uncovering new and evolving roles through genomic analysis.The power of solid supports in multiphase and droplet-based microfluidics: towards clinical applications.Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status.Effects of adjuvant chemotherapy in HER2-positive or triple-negative pT1ab breast cancers: a multi-institutional retrospective study.Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer.Establishment and external validation of a prognostic model for predicting disease-free survival and risk stratification in breast cancer patients treated with neoadjuvant chemotherapy
P2860
Q27006811-B5204BCF-3D1E-4E8F-8D03-BEEB66B35CB2Q27316870-93559EA9-3747-47AB-9402-62D5150C4016Q28260063-D59BBCD2-9628-449B-8269-91ADB66329A2Q33688726-75494892-1C98-4CB1-84CC-C2B9DC1520FBQ33798836-D51FA8C2-BB47-4244-98D3-D54BA5603847Q33812042-EBE0AB4F-743F-453A-9A0C-2DC56A1B8DB0Q33862786-BB391C16-3D1D-4862-9598-11901673F8CFQ34855870-8AD2E02F-8DF6-4547-9688-286EF1436A16Q34967515-6723D1E0-6914-4C9C-A688-B34DB086D3FDQ35041257-F6FAFABD-4731-4D6D-88C5-C91921A04006Q35239634-240E4A0F-01EC-45E1-8B39-75A381C77230Q35345516-EB1C722F-9B90-40E9-89CC-2DD6E10381ECQ35678436-04F2A108-E99E-4FB3-B370-04C86FC44698Q35740160-505BF114-202E-4106-B2BE-D7F7ED341515Q36119749-A0A1E3D7-EF62-404E-B551-E3B0A8A74C9BQ36245470-70B07C40-7EB4-4334-9CA5-8494BB871EFDQ36903095-CABDFDE4-F8A8-4B7E-9818-62624F67F339Q36978609-1142E6D4-5F44-4973-B840-A3D5256F0791Q37216946-31202379-BA77-4EE8-84BE-F07590DFD0CFQ37655890-A9F25958-7504-43BB-A3F8-60855CD4B671Q38111772-7E21E8F7-66DB-4A73-8C54-F98C8C0D7260Q38132239-32BA26DE-0080-4EAB-94A8-1975230D115DQ38314355-7807445B-2F50-413D-9BD6-A3985BBE3255Q38326102-330B547C-9BDA-4976-BCA3-2EB4559D3D58Q42377436-A710E52B-F263-4D66-A7EB-75ABF61AB5DEQ47217714-5664290F-E62E-4808-B4A3-045DE7A73679Q49832461-11176E09-08B8-4892-92F9-B378545C6221Q50899665-39A1B646-1CEF-4386-B80D-18C2D9322646Q54453782-93BF73E5-0630-489D-A40F-54BE35A018B3Q55466488-FBEE6C5A-BC41-4842-9819-CCCEEB56AF9EQ58806315-D7CD72B4-6E4C-4D3A-85AB-9B45754FD4F3
P2860
Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Predictability of adjuvant tra ...... O/CAP HER2-positivity criteria
@ast
Predictability of adjuvant tra ...... O/CAP HER2-positivity criteria
@en
type
label
Predictability of adjuvant tra ...... O/CAP HER2-positivity criteria
@ast
Predictability of adjuvant tra ...... O/CAP HER2-positivity criteria
@en
prefLabel
Predictability of adjuvant tra ...... O/CAP HER2-positivity criteria
@ast
Predictability of adjuvant tra ...... O/CAP HER2-positivity criteria
@en
P2093
P2860
P356
P1476
Predictability of adjuvant tra ...... O/CAP HER2-positivity criteria
@en
P2093
Ann E McCullough
Beiyun Chen
David W Hillman
Edith A Perez
Julie Gralow
Kathleen S Tenner
Leila A Kutteh
Lyndsay N Harris
Monica M Reinholz
Nancy E Davidson
P2860
P304
P356
10.1093/JNCI/DJR490
P407
P50
P577
2011-12-02T00:00:00Z